References
- Fisher RA. Theory of statistical estimation. Proceedings of the Cambridge Philosophical Society 1925;22:700-25
- Fisher RA. The arrangement of field experiments. Journal of the Ministry of Agriculture of Great Britain 1926;33:503-13
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 1959;22:719-48
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
- Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
- Haute Autorite de Sante. Indirect Comparisons: Methods and Validity. Paris, 2009
- Wells GA, Sultan SA, Chen L, et al. Indirect Evidence: Indirect Treatment Comparisons in Meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009
- National Institute for Health and Clinical Excellence. Guide to the Methods of Health Technology Assessment. London, 2013
- Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37
- Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313-24
- Ades AE. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med 2003;22:2995-3016
- Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
- Jansen JP, Fleurence F, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
- Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147
- Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR–AMCP–NPC Good Practice Task Force report. Value Health 2014;17:157-73
- Wu HY, Hwang JW, Lin HJ, et al. Comparative effectiveness of renin–angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ 2013;347:f6008
- Coluzzi F, Ruggeri M. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin 2014;30:1139-51
- Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27
- Nixon R, Capkun-Niggli G, Bergvall N, Dias S. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2015;31:51-2